Merck KGaA (MRK) Given a €93.00 Price Target at Credit Suisse Group
Credit Suisse Group set a €93.00 ($108.14) target price on Merck KGaA (FRA:MRK) in a report released on Wednesday morning. The brokerage currently has a neutral rating on the healthcare company’s stock.
Several other analysts also recently issued reports on MRK. Sanford C. Bernstein set a €105.00 ($122.09) target price on Merck KGaA and gave the company a buy rating in a research note on Tuesday, July 3rd. Berenberg Bank set a €104.00 ($120.93) target price on Merck KGaA and gave the company a buy rating in a research note on Wednesday, July 4th. Societe Generale set a €88.00 ($102.33) target price on Merck KGaA and gave the company a neutral rating in a research note on Wednesday, July 4th. JPMorgan Chase & Co. reissued a neutral rating on shares of Merck KGaA in a research note on Wednesday. Finally, Commerzbank set a €100.00 ($116.28) target price on Merck KGaA and gave the company a buy rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the stock. Merck KGaA has an average rating of Hold and an average target price of €98.76 ($114.84).
Shares of MRK opened at €93.72 ($108.98) on Wednesday. Merck KGaA has a 12-month low of €76.60 ($89.07) and a 12-month high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
Recommended Story: How is a Moving Average Calculated?
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.